Pilot studies in Pancreatic Cancer (R21) | Apply Online

Opportunity Summary:

The "Pilot studies in Pancreatic Cancer (R21)" opportunity (Funding Opportunity Number PA-08-208) is a National Cancer Institute (NCI), NIH funding announcement designed to push forward early-stage, innovative pancreatic cancer research. The central aim is to support exploratory or developmental projects that can open up new directions or generate strong preliminary data in areas that matter most to pancreatic cancer outcomes, including the cancer's underlying biology, what causes it (etiology), how it can be detected earlier or more accurately, and how it can be prevented or treated more effectively. A major emphasis is on work that brings together multiple disciplines, reflecting the idea that meaningful progress in pancreatic cancer often depends on combining expertise across fields rather than staying within a single research lane.

The award uses the NIH R21 mechanism, which is specifically meant for pilot and exploratory studies that may be higher-risk or less mature than a typical full research project, but potentially high-impact if successful. In practical terms, this mechanism supports the kind of research that can test a new concept, develop a novel tool or approach, or produce proof-of-principle evidence that later justifies a larger, more definitive grant. This FOA is also described as running in parallel with a companion announcement of the same scientific scope, PA-08-209, which uses the R03 mechanism. That parallel structure signals that applicants with smaller, more limited-scope projects may have an alternative route (R03), while projects needing the exploratory/developmental scale typical of an R21 can use PA-08-208.

Financially, the listed award ceiling is $200,000, and there is no cost sharing or matching requirement, meaning applicants are not required to provide additional non-federal funds to secure the award. The number of awards was not predetermined; awards depend on how much funding is available and how many applications are both submitted and judged to be highly meritorious. The opportunity is categorized as a discretionary grant and is associated with several CFDA numbers tied to cancer research areas: cancer cause and prevention (93.393), detection and diagnosis (93.394), treatment (93.395), biology (93.396), and cancer control (93.399). This range reinforces that the program is intentionally broad, covering the full continuum from understanding disease mechanisms through to improving patient-centered outcomes.

Eligibility is expansive and includes many organization types. Eligible applicants include small businesses, other for-profit organizations, state governments, public and state-controlled institutions of higher education, private institutions of higher education, and nonprofit organizations (both those with 501(c)(3) status and certain nonprofits without that status, with a noted exception/clarification in the full eligibility text). The announcement also explicitly includes additional eligible applicants such as federal agencies, Hispanic-serving institutions, non-U.S. entities (foreign organizations), regional organizations, and U.S. territories or possessions. This wide eligibility scope suggests NCI was aiming to attract a diverse pipeline of ideas and to allow strong pancreatic cancer concepts to compete regardless of whether they originate in academia, government, nonprofit research, or industry.

Key administrative details place this as a time-limited, archived opportunity. It was posted July 18, 2008, created December 5, 2008, with an original and current closing date of September 7, 2011, and an archive date of October 8, 2011. In other words, the announcement itself is no longer open, but it provides a clear snapshot of the type of exploratory pancreatic cancer research NCI was seeking under the R21 framework at that time. For the complete archived announcement, the source link is provided (http://grants.nih.gov/grants/guide/pa-files/PA-08-208.html), and technical access issues were directed to the NIH Office of Extramural Research (OER) webmaster contact listed in the notice.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: PPilot studies in Pancreatic Cancer (R03)

Previous opportunity: Investigations on Primary Immunodeficiency Diseases (R01)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 08 208

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 08 208) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 08 208", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.